227 related articles for article (PubMed ID: 34421888)
1. Immunotherapy for Dogs: Still Running Behind Humans.
Klingemann H
Front Immunol; 2021; 12():665784. PubMed ID: 34421888
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Dogs: Running Behind Humans.
Klingemann H
Front Immunol; 2018; 9():133. PubMed ID: 29459862
[TBL] [Abstract][Full Text] [Related]
3. Cancer Immunotherapies.
Bergman PJ
Vet Clin North Am Small Anim Pract; 2019 Sep; 49(5):881-902. PubMed ID: 31186125
[TBL] [Abstract][Full Text] [Related]
4. A Role for Dogs in Advancing Cancer Immunotherapy Research.
Dow S
Front Immunol; 2019; 10():2935. PubMed ID: 32010120
[TBL] [Abstract][Full Text] [Related]
5. Cellular Immunotherapy of Canine Cancer.
Addissie S; Klingemann H
Vet Sci; 2018 Dec; 5(4):. PubMed ID: 30563208
[TBL] [Abstract][Full Text] [Related]
6. Generation and Validation of an Antibody to Canine CD19 for Diagnostic and Future Therapeutic Purposes.
Haran KP; Lockhart A; Xiong A; Radaelli E; Savickas PJ; Posey A; Mason NJ
Vet Pathol; 2020 Mar; 57(2):241-252. PubMed ID: 32081102
[TBL] [Abstract][Full Text] [Related]
7. An Overview of Immunotherapeutic Approaches Against Canine Visceral Leishmaniasis: What Has Been Tested on Dogs and a New Perspective on Improving Treatment Efficacy.
Gonçalves AAM; Leite JC; Resende LA; Mariano RMDS; Silveira P; Melo-Júnior OAO; Ribeiro HS; de Oliveira DS; Soares DF; Santos TAP; Marques AF; Galdino AS; Martins-Filho OA; Dutra WO; da Silveira-Lemos D; Giunchetti RC
Front Cell Infect Microbiol; 2019; 9():427. PubMed ID: 31921703
[TBL] [Abstract][Full Text] [Related]
8. Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.
Sakai O; Igase M; Mizuno T
Vet Comp Oncol; 2020 Dec; 18(4):739-752. PubMed ID: 32329214
[TBL] [Abstract][Full Text] [Related]
9. Comparative Immunology and Immunotherapy of Canine Osteosarcoma.
Mason NJ
Adv Exp Med Biol; 2020; 1258():199-221. PubMed ID: 32767244
[TBL] [Abstract][Full Text] [Related]
10. Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs.
Yannelli JR; Wouda R; Masterson TJ; Avdiushko MG; Cohen DA
Vet Immunol Immunopathol; 2016 Dec; 182():95-100. PubMed ID: 27863558
[TBL] [Abstract][Full Text] [Related]
11. Translational oncotargets for immunotherapy: From pet dogs to humans.
Mestrinho LA; Santos RR
Adv Drug Deliv Rev; 2021 May; 172():296-313. PubMed ID: 33705879
[TBL] [Abstract][Full Text] [Related]
12. There and back again: Translating adoptive cell therapy to canine cancer and improving human treatment.
Brill SA; Thamm DH
Vet Comp Oncol; 2021 Sep; 19(3):420-427. PubMed ID: 34169631
[TBL] [Abstract][Full Text] [Related]
13. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.
Igase M; Nemoto Y; Itamoto K; Tani K; Nakaichi M; Sakurai M; Sakai Y; Noguchi S; Kato M; Tsukui T; Mizuno T
Sci Rep; 2020 Oct; 10(1):18311. PubMed ID: 33110170
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for canine cancer--is it time to go back to the future?
Killick DR; Stell AJ; Catchpole B
J Small Anim Pract; 2015 Apr; 56(4):229-41. PubMed ID: 25704119
[TBL] [Abstract][Full Text] [Related]
15. Sarcomas-A barren immunological wasteland or field of opportunity for immunotherapy?
Atherton MJ; Lenz JA; Mason NJ
Vet Comp Oncol; 2020 Dec; 18(4):447-470. PubMed ID: 32246517
[TBL] [Abstract][Full Text] [Related]
16. Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy.
Hutchison S; Sahay B; de Mello SC; Sayour EJ; Lejeune A; Szivek A; Livaccari AM; Fox-Alvarez S; Salute M; Powers L; Milner RJ
Vet Immunol Immunopathol; 2019 Oct; 216():109912. PubMed ID: 31446208
[TBL] [Abstract][Full Text] [Related]
17. The immunotherapy of canine osteosarcoma: a historical and systematic review.
Wycislo KL; Fan TM
J Vet Intern Med; 2015; 29(3):759-69. PubMed ID: 25929293
[TBL] [Abstract][Full Text] [Related]
18. Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy.
Cejalvo T; Perisé-Barrios AJ; Del Portillo I; Laborda E; Rodriguez-Milla MA; Cubillo I; Vázquez F; Sardón D; Ramirez M; Alemany R; Del Castillo N; García-Castro J
Cancer Res; 2018 Sep; 78(17):4891-4901. PubMed ID: 29991502
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy.
Barth SM; Schreitmüller CM; Proehl F; Oehl K; Lumpp LM; Kowalewski DJ; Di Marco M; Sturm T; Backert L; Schuster H; Stevanović S; Rammensee HG; Planz O
PLoS One; 2016; 11(11):e0167017. PubMed ID: 27893789
[TBL] [Abstract][Full Text] [Related]
20. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM
Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
